SummitTX Capital’s Axsome Therapeutics AXSM Stock Holding History

SummitTX Capital’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-15,304	Closed	-$2.59M	–	785
2026 Q1	$2.59M	Buy	+15,304	New	+$2.64M	0.08%	261
2025 Q4	–	Sell	-15,350	Closed	-$1.86M	–	703
2025 Q3	$1.86M	Buy	15,350 +12,641	+467%	+$1.42M	0.08%	268
2025 Q2	$283K	Buy	+2,709	New	+$287K	0.01%	628

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SummitTX Capital's AXSM Position: Q2 2026 in Review

SummitTX Capital sold out of Axsome Therapeutics (AXSM) in Q2 2026, closing a stake of 15,304 shares — an estimated $2.59M sold.

SummitTX Capital first reported a position in AXSM in Q2 2025 and held it in 3 quarters. The position peaked at $2.59M in Q1 2026. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

SummitTX Capital reported no remaining Axsome Therapeutics position as of Q2 2026 after selling out during the quarter.
SummitTX Capital sold 15,304 Axsome Therapeutics shares in Q2 2026, an estimated $2.59M.
SummitTX Capital first reported a position in Axsome Therapeutics in Q2 2025 and held it in 3 quarters.
SummitTX Capital's Axsome Therapeutics position peaked at $2.59M in Q1 2026.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.